Is It Still Relevant to Discover New ACE Inhibitors from Natural Products? YES, but Only with Comprehensive Approaches to Address the Patients’ Real Problems: Chronic Dry Cough and Angioedema [PDF]
Molecules, 2023 Despite many publications related to the identification of new angiotensin-I-converting enzyme (ACE) inhibitors, especially peptides from natural products, the actual reason/s for why new ACE inhibitors need to be discovered are yet to be fully ...
Sivananthan Manoharan
doaj +2 more sources
Utilizing Proteomic Approaches to Uncover the Neuroprotective Effects of ACE Inhibitors: Implications for Alzheimer’s Disease Treatment [PDF]
Molecules, 2023 Two types of angiotensin-converting enzyme (ACE) inhibitors, lisinopril and benazepril HCl, were tested in neuroblastoma cells and found to upregulate low-density lipoprotein-receptor-related protein 1B (LRP1B) and 14-3-3 protein zeta/delta. Additionally,
Ming-Hui Yang +6 more
doaj +2 more sources
ACE Inhibitors Boost Mobility and Muscle Strength by Reducing Intestinal Permeability in Older Adults with Alzheimer’s Disease [PDF]
PharmaceuticalsObjectives: Hypertension is common in Alzheimer’s disease (AD) and contributes to functional decline. While ACE inhibitors are widely used for hypertension, their systemic effects on intestinal permeability and physical capacity in AD patients remain ...
Rizwan Qaisar +5 more
doaj +2 more sources
Five-Membered Nitrogen Heterocycles Angiotensin-Converting Enzyme (ACE) Inhibitors Induced Angioedema: An Underdiagnosed Condition [PDF]
PharmaceuticalsAngiotensin-converting enzyme (ACE) inhibitors are used primarily in the treatment of hypertension, heart failure, and in the acute phase of myocardial infarction. Lisinopril [N2-[(1S)-1-car-boxy-3-phenylpropyl]-L-lysyl-L-proline], enalapril [(S)-1-[N-[1-
Niki Papapostolou +3 more
doaj +2 more sources
Abstract ACE inhibitors were first introduced because of their vasodilatory properties. It is now understood that the beneficial effects arise from the antagonism of the renin–angiotensin–aldosterone system. ACE inhibitors are first-line agents for all patients with HFrEF—this is also true in patients with asymptomatic LVSD.
Singh B, Cusick AS, Goyal A, Patel P.
europepmc +2 more sources
Cardiovascular Drugs and Therapy, 1993 There are chemical differences among angiotensin-converting enzyme (ACE) inhibitors that profoundly influence the pharmacokinetics and dynamics of different drugs. Differences in potency, affinity, and duration of action can be readily identified.
+12 more sources
QSAR studies of angiotensin converting enzyme inhibitors using CoMFA, CoMSIA and molecular docking [PDF]
Journal of the Serbian Chemical Society, 2021 In order to better understand the biochemical interactions governing their activities in lowering blood pressure, multiple quantitative structure-activity relationship (QSAR) models were developed from a data set of 58 angiotensin converting enzyme (ACE)
Tong Jian-Bo +3 more
doaj +1 more source
Use of ACE-inhibitors in Serbia in 2009 and 2010 [PDF]
Hospital Pharmacology, 2014 Introduction Cardiovascular diseases (CVD) are the most frequent cause of morbidity and mortality in many countries as well as in our country. That explains why medications for the treatment of CVD are the most used group of drugs.
Perić Dajana M. +5 more
doaj +1 more source
Conformational changes of blood ACE in chronic uremia. [PDF]
PLoS ONE, 2012 BACKGROUND: The pattern of binding of monoclonal antibodies (mAbs) to 16 epitopes on human angiotensin I-converting enzyme (ACE) comprise a conformational ACE fingerprint and is a sensitive marker of subtle protein conformational changes.
Maxim N Petrov +6 more
doaj +1 more source